Adtalem Global Education Inc. (NYSE:ATGE) Q4 2023 Earnings Call Transcript
Adtalem Global Education Inc. (NYSE:ATGE) Q4 2023 Earnings Call Transcript August 10, 2023
Adtalem Global Education Inc. beats earnings expectations. Reported EPS is $1.03, expectations were $0.97.
Operator: Greetings, and welcome to the Adtalem Global Education Fourth Quarter Fiscal Year 2023 Earnings Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jay Spitzer, Vice President of Investor Relations. Thank you, sir. You may begin.
Jay Spitzer: Good afternoon, ladies and gentlemen, and welcome to our earnings call for the fourth quarter and fiscal year 2023 results. On the call with me today are Steve Beard, President and Chief Executive Officer of Adtalem Global Education; and Bob Phelan, Chief Financial Officer. Before I hand you over to Steve, I, as usual, take you through the legal and safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute as forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changes in assumptions or otherwise.
Please see our latest Form 10-K, Form 10-Q for latest discussion of risk factors as it relate to forward-looking statements. In today’s presentation, we use certain non-GAAP financial measures, and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. You will find a link to the webcast on our Investor Relations website at investor.adtalem.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.
Steve Beard: Thanks, Jay. Good afternoon, everyone, and thank you for taking the time to join our fourth quarter and fiscal year 2023 earnings conference call. Fiscal year 2023 was another pivotal year for Adtalem as we achieved a number of significant milestones. For starters, we completed the integration of Walden and our legacy institutions into a complementary portfolio of like-kind institutions, all with the center of gravity in healthcare. We centralized our marketing and student experience capabilities into centers of excellence, where we can align and deploy best practices enterprise-wide and realize economies of scale and our efforts to enhance the student journey. We achieved our two-year $60 million cost synergy program, creating significant efficiencies and a more profitable operating model.
We expanded adjusted EBITDA margin to approximately 24% for fiscal year 2023, which is an increase of 200 basis points compared to fiscal year 2021. We’ve identified opportunities to invest for future growth, generate durable operating leverage, position ourselves to sustainably grow student enrollment, improve persistence and further expand our margin profile. Finally, we formally launched our growth with purpose strategy which focuses on improving and accelerating our performance across the critical value-creating activities of the business, while continuing to expand access for aspiring students and delivering high-quality academic outcomes. We’re still early in that journey, but growth with purpose is already building total enrollment momentum.
U.S. healthcare is struggling with a massive talent deficit that threatens the quality of care and exasperates health equities and communities across the country. We believe that we’ve uniquely repositioned Adtalem to serve as a scaled solution in addressing these challenges. Our post-secondary programs are rigorous, responsive to the workforce needs of the healthcare industry and serve to expand access to attractive careers through the delivery of high-quality academic outcomes for over 75,000 students and for over 25,000 diverse students that we graduated in 2023. Our graduates are serving in communities across the country, both urban and rural, and doing so in some of the best known and highly regarded health systems in the country. It’s no secret that opportunities for aspiring clinicians are exclusive and scarce.
At Adtalem, we address the current and growing provider shortages at scale through an inclusive and access-focused model that we believe is unrivaled today. With respect to our results, we ended fiscal year 2023 ahead of our most recent expectations and surpassed the goals that we established at the outset of the year. Full year revenue of $1.45 billion was up 5% for the year. Total enrollment trends have consistently improved throughout the year. Adjusted earnings per share ended the year at $4.21, increasing 35% year-over-year as our transformation and operational initiatives are generating their intended positive returns. Over the course of the year, we generated $169 million of free cash flow and returned $140 million to our owners through share repurchases.
Our balance sheet continues to remain strong, closing the year with $274 million in cash on hand and net leverage of 1.3x. As I mentioned earlier, we launched our Growth with Purpose strategy, which is designed to expand access and deliver enhanced student outcomes through optimizing five pillars of value creation: marketing, enrollment, retention, pricing and programs. In the fourth quarter and throughout the year, we refined our marketing strategy to deliver good results through the application of data-driven insights, refreshed brand campaigns and a more balanced approach to investments across the marketing funnel. We’re generating increased brand awareness, connecting with potential students at a deeper and more meaningful level and importantly, educating thousands about our flexible programs that meet students where, when and how they learn best.
The team is creating opportunities for our institutions to grow as inbound demand grew quarter-to-quarter with key programs such as RN to BSN program, our standard BSN program and our counseling programs leading the way. Increased demand has translated to double-digit year-over-year inquiry growth with all of our institutions achieving positive year-over-year inquiry growth in the fourth quarter. As part of the effort to sustainably grow enrollments, we remain committed to enhancing the student experience. Our enrollment teams have focused on streamlining and personalizing our engagement with prospective and existing students alike. In 2023, we launched our proactive affirmative registration process, which engaged over 18,000 students, simplifying the process to enrollment classes for the upcoming term.
In addition, through our self-service digital assistant tool for students, we’ve addressed over 750,000 Chamberlain and Walden student increase since January in real time and with a success rate of over 90%. These automated tools provide answers 24/7, affording our student-facing advisers more bandwidth and more opportunity to focus on engaging in personalized high-touch conversations with current and prospective students alike. Chamberlain University is expanding access both physically and online in markets with some of the highest nursing shortages. For example, in Atlanta, the demand for access to our curriculum is outpacing capacity at our existing campus. This September, we’ll welcome our first cohort of students at our new hybrid campus in Stockbridge, Georgia.
At scale, the Stockbridge campus will be able to accommodate up to 600 students, including 200 evening and weekend students. Collectively, these two locations will train up to 2,000 students, positively impacting Georgia’s nursing shortage. And as we’ve noted previously, Chamberlain’s campus footprint keeps us at the forefront of providing maximum flexibility for students with online, hybrid and campus-based pathways. We also continue to be pleased with progress at Walden. Our investments in brand and our shift in marketing mix have created momentum in new student growth, which is up over double digits in the fourth quarter on a year-over-year basis. And just as importantly, this growth was led by our nursing and social behavioral sciences programs.
Maxim Blinkov/Shutterstock.com
In addition, we’re particularly proud of the gains Walden continues to achieve in student persistence, which was up again in the fourth quarter. Moreover, the Higher Learning Commission in July renewed Walden’s national accreditation for a 10-year period. Shifting to Med/Vet. The Ross University School of Veterinary Medicine continues to operate near capacity with high persistence in matriculation. Inbound inquiry for both of our medical schools, the Ross University School of Medicine and the American University of the Caribbean School of Medicine remained high and up year-over-year in the fourth quarter. However, total enrollments for the quarter were lower year-over-year, driven by a combination of factors including a large graduating cohort, a sizable cohort on lead to prepare for Step 1 USMLE and a challenging May intake cycle that fell short of our expectations.
We’re obviously proud of the fact that we graduated a greater number of medical professionals this quarter compared to last year and that we were able to permit our students to persist in our programs through the pandemic. But to be sure, we have identified the conversion challenges contributing to the May intake shortfall and are already executing on remediation plans. I’m confident in the efficacy of those plans and expect total enrollment trends in Med/Vet to improve by the back half of 2024, returning to total enrollment growth as we exit the year. Temporary challenges notwithstanding, the value proposition of our medical schools remain strong. Focus on access, high-quality academic outcomes, including a five-year cumulative Step 1 USMLE pass rate of 89% from 2018 to 2022 as well as a 98% first-time residency attainment rate for 2022 and 2023 has tremendous appeal for aspiring physicians.
This value proposition, combined with our current focus on operational excellence, gives me confidence in the long-term growth prospects of our medical programs. In the quarter, we bolstered our in-house adaptive learning capabilities by entering into a perpetual license agreement with Edapt Technologies. Edapt is an adaptive learning platform that leverages proprietary data to enable students to learn at their own pace in the classroom and beyond. The software creates reinforcement learning loops and continually updates with real-time assessments to improve the mastery of content, focusing on positive individualized student outcomes. We’ve been testing and iterating this adaptive learning tool at Chamberlain with over 13,000 nursing students, and we’re really encouraged by the results.
This is another unique differentiator, driving personalized success as our students prepare for the NCLEX exam. In addition, we’ve already identified a number of additional use cases for adaptive learning tools to be applied across our institutions. On pricing, our optimization strategy is working. At Walden, the Believe and Achieve Scholarship program has been well received by students, outpacing our expectations as it incentivizes and rewards matriculation and student success. This is a great example of a win-win innovation of the kind being developed at Walden, lowering the cost of net tuition, financially incentivizing student matriculation to graduation and driving the realization of the lifetime value of enrollment. And finally, our fifth strategic pillar programs.
Walden’s competency-based Tempo program saw a 35% growth in new enrollments during the fourth quarter as a result of a new simplified strategy to strengthen the program positioning and launching a data-driven marketing campaign. Over at Chamberlain, specialty-focused tracks continue to generate significant interest with our MSN psychiatric mental health nurse practitioner program now enrolling over 1,700 students since launching two years ago. We’re also excited to bring to market our home health and kidney care, practice-ready specialty-focused models, which are being developed in partnership with leading providers like BrightStar Care and DaVita. With that, let me now provide some color on our outlook for fiscal 2024 that builds on the guide we provided during our Investor Day back in June.
We’re raising the low end of our guidance range for adjusted EPS and now anticipate adjusted earnings to be $4.20 to $4.40, while maintaining a revenue range of $1.46 billion to $1.52 billion. Fiscal 2024 is off to an encouraging start, driven by momentum in new enrollment and ongoing improvement in student persistence. Taken together, our strong foundation, integrated operating model, and growth with purpose strategy strike an optimal balance between investing to accelerate near-term performance and expanding profitability in the long term. I’m confident in our ability to return to total enrollment growth while maintaining our industry-leading margin profile during fiscal year 2024. In closing, I truly believe that the best way to positively impact the future of health care is to provide more people the opportunity to change it.
We’re uniquely positioned to help elevate standards of care, that’s compassionate and culturally confident by changing the face of those who deliver that care. As a mission-driven organization, we remain committed to advancing health equity and delivering diverse, highly qualified health care clinicians at scale. To that end, I want to thank the nearly 10,000 colleagues who continue to make Adtalem a force for good. It showed exemplary leadership, passion and willingness to go above and beyond, which upholds our commitment to our students and delivers positive outcomes. I’ll now hand the call over to Bob to take you through the fiscal year 2023 fourth quarter and fiscal year 2024 outlook in greater detail. Thank you.
Bob Phelan: Thanks, Steve, and hello, everyone. Our fourth quarter and full year results reflect our commitment to drive superior student outcomes while delivering financial results. The momentum from our strategic initiatives continues to in fiscal year top and bottom line growth as well as robust cash generation. I’ll start with a review of our financial results and key drivers for our performance in the fourth quarter and for the full year. Later in my remarks, I’ll discuss our expectations and assumptions for fiscal year 2024. Starting with the top line. Revenue in the fourth quarter increased by 1.1% to $364.6 million, driven by growth at Chamberlain and Walden, partially offset by Med/Vet. For the full year, revenue was $1.45 billion, up 5%.
The year-over-year revenue growth was driven primarily by the timing of the Walden acquisition as fiscal year 2023 had approximately one month of non-comparable contribution as well as revenue growth at Chamberlain and Med/Vet, a direct result of the momentum from our growth with purpose initiatives. During the quarter, consolidated adjusted operating income was $69.9 million and adjusted EBITDA was $83.3 million. This compares with $89.6 million and $104.7 million, respectively, during the prior year. Adjusted EBITDA margin was 22.8%. For the full year, consolidated adjusted operating income was $287.6 million, an increase of 7.5% versus the prior year, resulting in an operating margin of 19.8%, an increase of 40 basis points year-over-year.
Adjusted EBITDA for the full year was $343.4 million, an increase of 4.5% compared with the prior year. We continue to achieve a high adjusted EBITDA margin with the rate at 23.7%, while continuing to make strategic investments for sustainable long-term growth. I’m also happy to report that we successfully achieved our target of delivering $30 million in cost synergies, thus realizing our target of $60 million in synergies by the completion of the second anniversary of the Walden acquisition. Adjusted net income for the quarter was $45.3 million, and adjusted earnings per share was $1.03. For the full year, adjusted net income increased by 26% to $192.2 million, resulting in adjusted earnings per share of $4.21 or a 35% increase compared with the prior year as adjusted operating income growth, lower adjusted interest expense and diluted shares outstanding was partially offset by a higher adjusted effective tax rate.
Next, I’ll discuss financial highlights by segment. Chamberlain reported fourth quarter revenue of $144.5 million, an increase of 3% when compared with the prior year, driven by growth in enrollments and fee revenue. Total student enrollment during the quarter increased 1.2% compared with the prior year due to growth in pre-licensure and post-licensure nursing programs as well as higher persistence across the segment. Adjusted EBITDA decreased by 14.1% to $41.1 million as our underlying operational leverage was more than offset by the incremental investments in our marketing brand campaign and other expenses. Turning to Walden. Revenue in the fourth quarter was $138 million, an increase of 0.7% when compared with the prior year, driven by growth in nursing and social and behavioral health programs new student enrollment and our continued optimization of our net tuition pricing model.
Total student enrollment during the quarter decreased 4.8% compared with the prior year, primarily attributable to declines in non-healthcare programs, partially offset by higher persistence across the segment. Walden’s total enrollment was negatively impacted by 2.4% as a result of an operational initiative to eliminate certain off-cycle start dates as we previously discussed last quarter. Adjusted EBITDA decreased 9.4% to $35.3 million as segment operational efficiencies were offset by investments in marketing and brand campaigns. In the Medical and Veterinary segment, revenue in the fourth quarter decreased 1.5% to $82.1 million due to lower medical enrollments, which were largely offset by pricing favorability. Total student enrollment decreased 8.2% compared with the prior year, primarily due to lower-than-expected May starts at the medical schools.
Our veterinary school continues to operate near capacity. Adjusted EBITDA decreased by 37.1% to $14.7 million as we experienced lower revenue made investments in our brand campaigns for the three institutions and incurred higher costs across the other expense categories. As Steve mentioned in his remarks, we are already executing on remediation plans to improve enrollment in our medical schools and anticipate total enrollment trends to improve by the back half of 2024, returning to total enrollment growth exiting the year. We also remain focused on cost discipline and expect to maintain attractive margins in our Medical and Veterinary segment. Shifting gears to cash flow and balance sheet. During the year, we continued to drive significant improvements in free cash flow, which was $169 million for fiscal 2023, representing a 27% increase year-over-year, primarily due to improved operating results and lower interest expense.
We executed against our disciplined capital allocation philosophy during fiscal year 2023, investing in organic growth, while reducing debt and returning capital to our shareholders. More specifically, we paid down $150 million of our Term Loan B in the first half of fiscal year 2023, resulting in gross debt of $708 million at the end of fiscal 2023. This resulted in a 1.3 times net leverage ratio at year-end. We also repurchased 3.2 million shares during the year, $127 million returned to shareholders against our Board authorized $300 million authorization, with $13 million to close out the prior 2022 accelerated share repurchase program. Actions that we believe have increased long-term intrinsic value for the benefit of our owners. Turning to our fiscal year 2024 guidance.
Over the past two years, we’ve consistently delivered on commitments to our stakeholders and continue to operate with greater efficiency which has positioned us well for the future. As Steve mentioned earlier, we are reaffirming our revenue guidance to be in the range of $1.46 billion to $1.52 billion, representing low to mid-single-digit growth. We are raising the low end of our adjusted earnings per share by $0.05 to be in the range of $4.20 to $4.40. In addition, we expect to continue to generate strong cash flow, which will enable share repurchases and balance sheet flexibility. The phasing of our results during fiscal 2024 is worth noting. As Steve mentioned in his remarks, we are forecasting total enrollment trends to continue to improve throughout the year.
In turn, we anticipate revenue to follow this trend with a greater acceleration to occur in the back half of the year. Further, we are currently in a period of incremental growth investments as we deploy our growth with purpose strategy and take advantage of the opportunities that we see in the marketplace today, which is causing a short-term reduction to our adjusted EBITDA margin profile. As we stated at our Investor Day, we anticipate to maintain our high level of profitability and margin profile for the full year, but with higher investment levels earlier in the year and the accelerated revenue growth in the back half of the year. Our investments are already generating their intended returns and will build throughout the year. To conclude, I’m confident in our ability to grow as a purpose-driven organization, creating tremendous shareholder value.
We have a clear path forward that we believe will yield benefits for all our stakeholders for years to come. With that, I will now turn the call over to the operator for Q&A.
See also Top 12 Undervalued Tech Stocks According to Analysts and 10 Metals Stocks with Insider Buying.
To continue reading the Q&A session, please click here.
